Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K⁺ Channels: Role in the Adverse Drug Reactions

• Ngā kaituhi matua: Fatima Maqoud (Author), Rosa Scala (Author), Vincenzo Tragni (Author), Ciro Leonardo Pierri (Author), Maria Grazia Perrone (Author), Antonio Scilimati (Author), Domenico Tricarico (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2021-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Zoledronic acid (ZOL) is used as a bone-specific antiresorptive drug with antimyeloma effects. Adverse drug reactions (A.D.R.) are associated with ZOL-therapy, whose mechanics are unknown. ZOL is a nitrogen-containing molecule whose structure shows similarities with nucleotides, ligands of ATP-sensi...